NAV
$177.34
AUM
$642.8M
Expense Ratio
-
Dividend Yield
0.00%
Beta
0.94
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| +18.16% | +3.81% | +12.83% | +30.77% | +21.42% | +14.03% |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | NEM | Newmont Corp | 0.98% |
| 2 | MO | Altria Group Inc | 0.94% |
| 3 | BMY | Bristol-Myers Squibb Co | 0.91% |
| 4 | MRK | Merck & Co Inc | 0.89% |
| 5 | HCA | HCA Healthcare Inc | 0.87% |
| 6 | MCK | McKesson Corp | 0.84% |
| 7 | BNY | Bank of New York Mellon Corp | 0.84% |
| 8 | XOM | Exxon Mobil Corp | 0.83% |
| 9 | GILD | Gilead Sciences Inc | 0.83% |
| 10 | MU | Micron Technology Inc | 0.83% |
The fund invests primarily in U.S. common stocks with the potential to generate higher returns relative to the broad U.S. equity market by investing in stocks with relatively strong recent performance, strong fundamentals, and low prices relative to fundamentals as determined by the advisor. Under normal circumstances, at least 80% of its assets will be invested in securities issued by U.S. companies.
Inception Date: 2018-02-13